(Q33403209)
Statements
1 reference
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. (English)
1 reference
R Angelo de Claro
1 reference
Karen McGinn
1 reference
Virginia Kwitkowski
1 reference
Julie Bullock
1 reference
Aakanksha Khandelwal
1 reference
Bahru Habtemariam
1 reference
Yanli Ouyang
1 reference
Haleh Saber
1 reference
Kyung Lee
1 reference
Kallappa Koti
1 reference
Mark Rothmann
1 reference
Marjorie Shapiro
1 reference
Francisco Borrego
1 reference
Kathleen Clouse
1 reference
Xiao Hong Chen
1 reference
Janice Brown
1 reference
Lara Akinsanya
1 reference
Robert Kane
1 reference
Edvardas Kaminskas
1 reference
Ann Farrell
1 reference
Richard Pazdur
1 reference
7 September 2012
1 reference
1 reference
18
1 reference
21
1 reference
5845-5849
1 reference
Identifiers
1 reference
1 reference